Great Lakes Advisors LLC Sells 8,077 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Great Lakes Advisors LLC reduced its stake in Lantheus Holdings, Inc. by 18.3%, now owning 36,168 shares worth approximately $3.53 million.
• Lantheus reported a EPS of $1.57 for its latest quarter, falling short of analysts' estimates of $1.65, with revenues totaling $378.05 million.
• Various institutional investors have recently altered their positions in Lantheus, with Baird Financial Group Inc. significantly increasing its holdings by 579.7%.

Great Lakes Advisors LLC lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 18.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 36,168 shares of the medical equipment provider's stock after selling 8,077 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.05% of Lantheus worth $3,530,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Signaturefd LLC boosted its position in Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 116 shares during the last quarter. Quarry LP grew its stake in Lantheus by 2,350.0% during the first quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 470 shares during the period. Hughes Financial Services LLC bought a new stake in Lantheus in the first quarter worth approximately $81,000. UMB Bank n.a. lifted its stake in Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after buying an additional 633 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of Lantheus stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last 90 days. Corporate insiders own 1.50% of the company's stock.

Lantheus Price Performance

Lantheus stock traded down $2.05 during midday trading on Friday, reaching $52.94. 842,370 shares of the stock were exchanged, compared to its average volume of 1,507,125. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The firm has a market cap of $3.60 billion, a PE ratio of 14.08 and a beta of 0.15. The company's fifty day moving average is $63.98 and its 200-day moving average is $81.27.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same quarter last year, the firm earned $1.80 earnings per share. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research reports. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, Truist Financial set a $63.00 price target on Lantheus and gave the stock a "hold" rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and a consensus target price of $91.60.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.